Pathology findings and clinical outcomes after risk reduction salpingo-oophorectomy in BRCA mutation carriers: a multicenter Spanish study

• L. Minig ^[1] ; S. Cabrera ^[8] ; R. Oliver ^[9] ; A. Couso ^[2] ; M. J. Rubio ^[3] ; S. Iacoponi ^[10] ; M. B. Martin-Salamanca ^[4] ; S. Carballo-Rastrilla ^[5] ; J. M. Cádenas-Rebollo ^[6] ; A. García-Garcia ^[1] ; B. Gil-Ibáñez ^[8] ; M. J. Juan-Fita ^[1] ; M. G. Patrono ^[7]
  1. [1] Instituto Valenciano de Oncologia

     Instituto Valenciano de Oncologia

     Valencia, España

     
  2. [2] Hospital Universitario Príncipe de Asturias

     Hospital Universitario Príncipe de Asturias

     Alcalá de Henares, España

     
  3. [3] Hospital Universitario Reina Sofia

     Hospital Universitario Reina Sofia

     Cordoba, España

     
  4. [4] Hospital Universitario de Getafe

     Hospital Universitario de Getafe

     Getafe, España

     
  5. [5] Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Complejo Hospitalario Universitario Insular - Materno Infantil de Canarias

     Gran Canaria, España

     
  6. [6] Universidad CEU San Pablo

     Universidad CEU San Pablo

     Madrid, España

     
  7. [7] Hospital Italiano de Buenos Aires

     Hospital Italiano de Buenos Aires

     Argentina

     
  8. [8] Hospital Universitario Vall d`Hebron, España
  9. [9] Hospital Universitario Madrid, España
  10. [10] Hospital Universitario Quirón Madrid, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 20, Nº. 10 (October 2018), 2018, págs. 1337-1344
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Objective To determine the incidence of serous tubal intraepithelial carcinoma (STIC) after risk reduction salpingo-oophorectomy(RRSO), and to describe oncological outcomes after RRSO.

    Materials and methods BRCA pathogenic mutation carriers who had undergone an RRSO were evaluated in this retrospective multicenter observational study. Patients were only included when fallopian tubes were analyzed following the protocol for Sectioning and Extensively Examining the FIMbria (SEE-FIM). Surgeries were performed between June 2010 and April 2017 at eight Spanish hospitals.

    Results A total of 359 patients met the inclusion criteria. STIC was diagnosed in 3 (0.8%) patients; one of them underwent surgical staging due to positive peritoneal washing, with absence of disease at the final pathology report. None of the three patients received adjuvant chemotherapy and were free of disease at last follow-up. Fallopian tube and ovarian carcinoma were diagnosed in 5 (1.4%) and 1 (0.3%), respectively. At a median (range) follow-up time of 29 (3–92) months, five patients had a newly diagnosed breast cancer. Other types of cancer, which were diagnosed during the follow-up time, included: serous primary peritoneal carcinoma (n = 1), serous endometrial carcinoma (n = 1), colon (n = 1), pancreas (n = 1), jaw (n = 1), and lymphoma (n = 1). Seven patients died due to different types of cancer: breast (n = 4), pancreas (n = 1), jaw (n = 1), and colon (n = 1).

    Conclusion The incidence of STIC after RRSO in BRCA mutation carriers is low (0.8%) and it presents an excellent oncological outcome. Patients after RRSO, however, run the risk to develop other types of cancer during follow-up and should be properly advised before the prophylactic surgery.